Leading into Budget week in Canberra this week, was a journey in planning, months in advance by member based groups, to advocate for new policy and funding changes in the Australian Health System.
Some paths are taken because of new crises to be addressed in the workforce, others in considering new models of care to treat patients, or simply to get new medications onto the PBS.
Australian Health Journal met with a number of industry heads after the budget on their journeys so far in lobbying for change, their achievements, some of the disappointments and their thoughts on the road ahead, with an election round the corner.
Skip ahead:
00:35 Tegan Carrison, Executive Director Australian Association of Psychologists Inc (AAPi)
03:12 John Bruning, CEO Australasian College of Paramedicine (ACP)
09:09 Paul Sadler, CEO Aged and Community Services Australia (ACSA)
12:06 Karen Booth, President Australian Primary Health Care Association (APNA)
19:45 Jo Armstrong, CEO Cystic Fibrosis Australia
23:25 Elizabeth de Somer, CEO Medicines Australia
You Might also like
-
Student nurse placements in primary health care
With an urgent need to manage increasing rates of chronic disease, an ageing population, and a rapidly-ageing primary health care nurse workforce, Australia desperately needs more primary health care nurses to enter the workforce before the current generation retires and cannot pass on its skills.
Most nurses start their career in a hospital. Historically, it was difficult for universities and tertiary education providers to arrange placements for student nurses in primary health care. However, the APNA Student Nurse Placement Program provides student nurses with a foot in the door to a career in vibrant primary health care settings such as general practice or community health to perform supervised activities.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.